How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
AUTOR(ES)
Perini, Guilherme Fleury; Fischer, Thais; Gaiolla, Rafael Dezen; Rocha, Talita Bueno; Bellesso, Marcelo; Teixeira, Larissa Lane Cardoso; Delamain, Marcia Torresan; Scheliga, Adriana Alves de Souza; Ribeiro, Glaciano Nogueira; Vaz Neto, Jorge; Baiocchi, Otávio Cesar Carvalho Guimaraes; Abdo, André Neder Ramires; Arrais-Rodrigues, Celso; Fogliatto, Laura M.; Bigni, Ricardo de Sá; Schaffel, Rony; Biasoli, Irene; Pereira, Juliana; Nabhan, Samir Kanaan; Souza, Cármino Antônio de; Chiattone, Carlos Sérgio
FONTE
Hematol., Transfus. Cell Ther.
DATA DE PUBLICAÇÃO
2020-06
RESUMO
ABSTRACT: The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.
Documentos Relacionados
- Otorhinolaryngologists and Coronavirus Disease 2019 (COVID-19)
- Coronavirus disease 2019 (COVID-19) in Brasil: information to physical therapists
- A pragmatic approach and treatment of coronavirus disease 2019 (COVID-19) in intensive care unit
- O impacto real da doença do coronavirus 2019 (covid-19) no desfecho da gestação
- Anosmia/Hyposmia is a Good Predictor of Coronavirus Disease 2019 (COVID-19) Infection: A Meta-Analysis